Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) PT at $25.60

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has earned an average recommendation of “Moderate Buy” from the seventeen analysts that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $25.25.

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. StockNews.com cut shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. HC Wainwright restated a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Raymond James restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. Finally, Guggenheim downgraded ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their target price for the stock from $23.00 to $20.00 in a research note on Friday.

Insider Buying and Selling

In other news, insider James Kihara sold 4,073 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $68,467.13. Following the completion of the sale, the insider now owns 19,863 shares in the company, valued at approximately $333,897.03. This trade represents a 17.02 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Mark C. Schneyer sold 10,259 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $172,453.79. Following the completion of the transaction, the chief financial officer now directly owns 53,302 shares of the company’s stock, valued at approximately $896,006.62. This represents a 16.14 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,661 shares of company stock valued at $414,551. Corporate insiders own 28.30% of the company’s stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Park Place Capital Corp purchased a new stake in ACADIA Pharmaceuticals in the third quarter worth $25,000. Values First Advisors Inc. purchased a new position in ACADIA Pharmaceuticals in the third quarter worth about $27,000. Quest Partners LLC increased its stake in ACADIA Pharmaceuticals by 42.3% in the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 1,047 shares in the last quarter. Stonepine Capital Management LLC purchased a new position in shares of ACADIA Pharmaceuticals in the second quarter worth $81,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of ACADIA Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,999 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 1,066 shares in the last quarter. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Stock Down 5.2 %

Shares of NASDAQ ACAD opened at $17.46 on Thursday. The company has a market cap of $2.91 billion, a PE ratio of 22.38 and a beta of 0.37. The business’s 50 day moving average price is $16.86 and its two-hundred day moving average price is $16.44. ACADIA Pharmaceuticals has a twelve month low of $14.15 and a twelve month high of $31.10.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm had revenue of $250.40 million during the quarter, compared to the consensus estimate of $248.83 million. During the same quarter in the previous year, the firm posted ($0.40) EPS. The business’s revenue for the quarter was up 18.3% compared to the same quarter last year. As a group, research analysts anticipate that ACADIA Pharmaceuticals will post 0.73 EPS for the current fiscal year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.